FINWIRES · TerminalLIVE
FINWIRES

ASX:BIO

4 stories mentioning ASX:BIO

Every FINWIRES story that references ASX:BIO, newest first.

Asia

Biome Signs Binding Commercial Manufacturing Agreement for Activated Probiotics Products in Australia

Biome Australia (ASX:BIO) signed a binding commercial manufacturing agreement with Specialty Probiotics Australia, with an initial term of two years, as it seeks to transition manufacturing of its Activated Probiotics range to Australia, according to a Wednesday Australian bourse filing.The agreement requires no capital expenditure from Biome, and production in Australia will occur in smaller, more frequent batches. The first commercial batch is targeted for September, with the remaining range expected to move over around the following 18 months, subject to successful commercial scale-up and transition of production.Biome will supply the active ingredients, and Specialty Probiotics will carry out domestic manufacture and finishing.Biome will maintain its supply relationships with its European manufacturing partners to continue servicing European markets.

ASX:BIO
Asia

Biome Australia Adds Greece Site to Lactiplantibacillus Plantarum Clinical Trial, Shares Jump 4%

Biome Australia (ASX:BIO) said the multi-center clinical trial of its first wholly proprietary strain, BMB18, or Lactiplantibacillus plantarum, was expanded from a single-centre study at La Trobe University in Melbourne with the activation of Harokopio University of Athens in Greece as a concurrent second site, according to a Wednesday Australian bourse filing.The three-arm, double-blind, placebo-controlled study will test two BMB18 dosage levels against placebo across 240 participants over a six-week intervention period with a two-week follow-up.Pre-clinical work showed that the strain has the potential for a triple mechanism of action across intestinal barrier function, immunomodulation, and antioxidant activity.Recruitment is expected to begin this week at both sites, and the trial is expected to start in the fourth quarter of fiscal year 2026.Its shares rose 4% in recent trading on Wednesday.

ASX:BIO
Asia

Biome Australia Extends Supply Deal With Probiotical Through 2028

Biome Australia (ASX:BIO) has extended its exclusive supply agreement with partner Probiotical by two years through 2028, according to a Tuesday filing with the Australian bourse.The agreement was due to expire in June and was extended on existing commercial terms, per the filing.The extension comes as Biome looks to scale its presence across Australia, Canada, the UK, Ireland, and New Zealand.

ASX:BIO
Asia

Biome Australia Files Inaugural Patent Application for Probiotic Strain

Biome Australia (ASX:BIO) filed its inaugural patent application for probiotic strain BMB18, according to a Monday filing with the Australian bourse.Human clinical trial on the BMB18 strain is expected to be conducted with La Trobe University in the fourth quarter of the year, the filing said.Shares rose nearly 1% in afternoon trade Monday.

ASX:BIO
ASX:BIO News | FINWIRES